Drug Profile
Research programme: proto-oncogene protein c-met inhibitors - Pfizer
Alternative Names: PF 2362376Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteosarcoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteosarcoma in USA
- 08 May 2007 Preclinical trials in Osteosarcoma in USA (unspecified route)
- 08 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section